<DOC>
	<DOCNO>NCT00796640</DOCNO>
	<brief_summary>The purpose study compare bioavailability 2 extend release paliperidone pellet formulation fast fed condition 2 mg paliperidone oral solution fast condition . Additional objective compare pharmacodynamic effect ( postural change blood pressure heart rate ) , evaluate safety tolerability treatment , explore relationship CYP2D6 genotype paliperidone exposure .</brief_summary>
	<brief_title>A Pharmacokinetics Pharmacodynamics Study Under Fasting Fed Conditions With Paliperidone Extended-release Immediate-release Formulations</brief_title>
	<detailed_description>This single-center , open-label , randomize , 5-way crossover Phase 1 study non-smoking healthy men woman , age 18 55 year . The study consist screen period ; 5-way crossover , open-label treatment phase 14 day washout treatment ; end-of-study evaluation upon completion early withdrawal . Eligible volunteer randomly assign 1 5 treatment sequence . Each volunteer receive follow treatment random order : ( A ) paliperidone ER pellet formulation-1 , 1 capsule 2.5 mg , fast condition ; ( B ) paliperidone ER pellet formulation-1 , capsule 2.5 mg food ( high-fat breakfast ) ; ( C ) paliperidone ER pellet formulation-2 1 capsule 2.5 mg , fast condition ; ( D ) paliperidone ER pellet formulation-2 1 capsule 2.5 mg food ( high-fat breakfast ) ; ( E ) immediate release ( IR ) paliperidone oral solution , 2 mg ( 2 mL ) 1-mg/mL solution , fast condition . Alternative paliperidone ER formulation develop aim increase bioavailability reduce variability , without compromise favorable effect orthostatic hypotension see ER OROS paliperidone . Therefore , study , pharmacokinetics pharmacodynamic property , well effect food , 2 alternative paliperidone ER pellet formulation investigate . Safety tolerability monitor throughout study.. Single dose paliperidone ER pellet formulation-1 , 1 capsule 2.5 mg , fast ; paliperidone ER pellet formulation-1 , 1 capsule 2.5 mg food ( high-fat breakfast ) ; paliperidone ER pellet formulation-2 1 capsule 2.5 mg , fast ; paliperidone ER pellet formulation-2 1 capsule 2.5 mg food ( high-fat breakfast ) ; IR paliperidone oral solution , 2 mg ( 2 mL ) 1-mg/mL solution , fast .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Body mass index ( weight [ kg ] /height ( ) ² ) range 18.0 28.0 kg/m² , inclusive Normotensive supine ( 5 minute ) blood pressure 100 140 mmHg systolic , inclusive , diastolic 60 90 mmHg , inclusive Healthy basis prestudy physical examination , medical history , electrocardiogram , laboratory result blood biochemistry , hematology urinalysis perform within 21 day first dose . If result biochemistry , hematology urinalysis test within laboratory 's reference range volunteer include investigator judge deviation clinically significant . For liver function test ( alanine transaminase , aspartate transaminase , bilirubin ) , value must contain within 2 time upper limit normal laboratory reference range renal function test , value must within normal laboratory reference range Women must postmenopausal least 1 year , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization discretion investigator , total abstinence ) entry throughout study , well negative serum pregnancy test screening . To ensure continued eligibility , woman must negative urine test dose study drug ( Day 1 period ) . Known allergy history significant hypersensitivity heparin Recent history alcohol substance abuse . Test positive urine drug screen screen urine drug screen alcohol breath test Day 1 Period 1 Relevant history cardiovascular , respiratory , neuropsychiatric , renal , hepatic , gastrointestinal ( include surgery , malabsorption problem ) , endocrine , immunologic diseases A decrease great equal 20 mmHg systolic blood pressure 3 minute stand , symptom lightheadedness , dizziness faint upon stand screen Positive result serology test ( hepatitis B , C HIV ) Have less 1 bowel movement average day History cancer , exception basal cell carcinoma History smoking use nicotinecontaining substance within last 2 month , determine medical history and/or volunteer 's verbal report . ( Volunteers must agree refrain use throughout study . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>ER Paliperidone</keyword>
</DOC>